ERBB2 and breast cancer: As the most aggressive subtype of breast cancer, triple-negative breast cancer (TNBC) constituted roughly 15 to 20% of patients with breast cancer and was defined to lack the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (Her-2) markers [2].